BIO Bio-Rad Laboratories Inc

Price (delayed)

$790.32

Market cap

$23.53B

P/E Ratio

5.82

Dividend/share

N/A

EPS

$135.83

Enterprise value

$23.01B

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, ...

Highlights
The EPS has soared by 108% YoY
The net income has soared by 108% YoY
The price to earnings (P/E) is 93% lower than the 5-year quarterly average of 79.8 but 28% higher than the last 4 quarters average of 4.5

Key stats

What are the main financial stats of BIO
Market
Shares outstanding
29.77M
Market cap
$23.53B
Enterprise value
$23.01B
Valuations
Price to earnings (P/E)
5.82
Price to book (P/B)
2.03
Price to sales (P/S)
8.17
EV/EBIT
4.4
EV/EBITDA
4.4
EV/Sales
7.99
Earnings
Revenue
$2.88B
EBIT
$5.23B
EBITDA
$5.23B
Free cash flow
$586.53M
Per share
EPS
$135.83
Free cash flow per share
$19.71
Book value per share
$389.57
Revenue per share
$96.76
TBVPS
$491.9
Balance sheet
Total assets
$15.12B
Total liabilities
$3.52B
Debt
$212.04M
Equity
$11.59B
Working capital
$1.7B
Liquidity
Debt to equity
0.02
Current ratio
3.9
Quick ratio
2.67
Net debt/EBITDA
-0.1
Margins
EBITDA margin
181.5%
Gross margin
56.6%
Net margin
140.5%
Operating margin
17.7%
Efficiency
Return on assets
29.9%
Return on equity
39.6%
Return on invested capital
43.9%
Return on capital employed
36%
Return on sales
181.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
0.65%
1 week
-3.63%
1 month
1.26%
1 year
54.51%
YTD
35.57%
QTD
22.67%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.88B
Gross profit
$1.63B
Operating income
$510.49M
Net income
$4.05B
Gross margin
56.6%
Net margin
140.5%
BIO's operating income has surged by 110% year-on-year and by 17% since the previous quarter
The net income has soared by 108% YoY
BIO's operating margin has surged by 67% year-on-year and by 9% since the previous quarter
The net margin has surged by 65% year-on-year but it has declined by 7% since the previous quarter

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
P/E
5.82
P/B
2.03
P/S
8.17
EV/EBIT
4.4
EV/EBITDA
4.4
EV/Sales
7.99
The EPS has soared by 108% YoY
The price to earnings (P/E) is 93% lower than the 5-year quarterly average of 79.8 but 28% higher than the last 4 quarters average of 4.5
The equity has soared by 58% YoY and by 9% from the previous quarter
BIO's P/B is 19% above its last 4 quarters average of 1.7 and 6% above its 5-year quarterly average of 1.9
The stock's price to sales (P/S) is 89% more than its 5-year quarterly average of 4.3 and 23% more than its last 4 quarters average of 6.6
The revenue has grown by 26% YoY and by 7% from the previous quarter

Efficiency

How efficient is Bio-Rad Laboratories business performance
The ROS has soared by 64% YoY but it has decreased by 8% from the previous quarter
Bio-Rad Laboratories's ROA has increased by 31% YoY but it has decreased by 10% from the previous quarter
The company's return on invested capital rose by 27% YoY but it fell by 12% QoQ
The ROE is up by 25% year-on-year but it is down by 11% since the previous quarter

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The company's quick ratio has surged by 76% YoY and by 14% QoQ
The company's current ratio has surged by 70% YoY and by 9% QoQ
The debt is 98% smaller than the equity
Bio-Rad Laboratories's debt to equity has plunged by 78% YoY
The debt has dropped by 67% year-on-year and by 3.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.